Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals Llc (ACXP)
:ACXP
ACXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.80 - $44.00
Previous CloseN/A
Volume243.54K
Average Volume (3M)72.56K
Market Cap
$6.61M
Enterprise Value$6.10M
Total Cash (Recent Filing)$6.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 18, 2025EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding1,584,775
10 Day Avg. Volume40,301
30 Day Avg. Volume72,557
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$30.50Price Target Upside631.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIbezapolstat demonstrated a 94% clinical cure rate and no recurrence at 30 days, a key measure in CDI antibiotic development.
Drug DevelopmentThe company should now be better positioned to raise additional capital to continue its development of its DNA polymerase IIIC inhibitor antibiotics, including lead candidate ibezapolstat for C difficile.
Regulatory SupportRegulatory agencies in the U.S. and the E.U. have provided positive feedback to Acurx, supporting topics and plans related to manufacturing, non-clinical, and clinical aspects of the Phase 3 program and trial design.
Bears Say
CompetitionIbezapolstat has demonstrated positive impacts on the gut microbiome, something that standard of care vancomycin or fidaxomicin cannot do.
Partnership ChallengesAcurx should be able to find a partner for its development program, enhancing its prospects for growth and collaboration.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals Llc’s price range in the past 12 months?
Acurx Pharmaceuticals Llc lowest stock price was $3.80 and its highest was $44.00 in the past 12 months.
What is Acurx Pharmaceuticals Llc’s market cap?
Acurx Pharmaceuticals Llc’s market cap is $6.61M.
When is Acurx Pharmaceuticals Llc’s upcoming earnings report date?
Acurx Pharmaceuticals Llc’s upcoming earnings report date is Nov 18, 2025 which is in 62 days.
How were Acurx Pharmaceuticals Llc’s earnings last quarter?
Acurx Pharmaceuticals Llc released its earnings results on Aug 12, 2025. The company reported -$1.89 earnings per share for the quarter, beating the consensus estimate of -$2.333 by $0.443.
Is Acurx Pharmaceuticals Llc overvalued?
According to Wall Street analysts Acurx Pharmaceuticals Llc’s price is currently Undervalued.
Does Acurx Pharmaceuticals Llc pay dividends?
Acurx Pharmaceuticals Llc does not currently pay dividends.
What is Acurx Pharmaceuticals Llc’s EPS estimate?
Acurx Pharmaceuticals Llc’s EPS estimate is -1.31.
How many shares outstanding does Acurx Pharmaceuticals Llc have?
Acurx Pharmaceuticals Llc has 1,584,775 shares outstanding.
What happened to Acurx Pharmaceuticals Llc’s price movement after its last earnings report?
Acurx Pharmaceuticals Llc reported an EPS of -$1.89 in its last earnings report, beating expectations of -$2.333. Following the earnings report the stock price went down -0.893%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals Llc?
Currently, no hedge funds are holding shares in ACXP
Company Description
Acurx Pharmaceuticals Llc
Acurx Pharmaceuticals (ACXP) is a clinical-stage biopharmaceutical company focused on developing new antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, the Centers for Disease Control and Prevention, and the Food and Drug Administration. The company's lead product candidate, ibezapolstat, is designed to address the growing challenge of antibiotic resistance, specifically targeting Clostridioides difficile infections. Acurx is committed to advancing its pipeline of novel antibiotic compounds to meet the critical need for new treatments in infectious disease care.
ACXP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including a new patent, additional funding, and significant clinical trial results. Financial results showed improvement with increased cash reserves and reduced expenses. However, challenges such as the reverse stock split and strategic delays in clinical trials were noted. Overall, the sentiment is cautiously optimistic.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$30.50
▲(631.41% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―
Ownership Overview
8.10% Insiders
2.23% Mutual Funds
0.37% Other Institutional Investors
87.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---